<DOC>
	<DOC>NCT02405039</DOC>
	<brief_summary>This is a randomized, double masked study designed to evaluate the safety of EBI-005 5 mg/mL topical ophthalmic solution given three times daily (TID) compared to vehicle-control over a one year period in subjects with dry eye disease (DED). Approximately 188 subjects will be enrolled to either EBI-005 or vehicle at up to 15 centers in the United States (US) and Canada.</brief_summary>
	<brief_title>Study of EBI-005 in Dry Eye Disease (DED)</brief_title>
	<detailed_description />
	<mesh_term>Keratoconjunctivitis Sicca</mesh_term>
	<mesh_term>Dry Eye Syndromes</mesh_term>
	<mesh_term>Eye Diseases</mesh_term>
	<criteria>Key 1. Have a history of dry eye disease (DED) in both eyes supported by a previous clinical diagnosis or have a selfreported history of subjective complaints for at least 6 months prior to Visit 1 2. Are willing and able to follow instructions and can be present for the required study visits for the duration of the study Key 1. Have an ocular condition that could confound study assessments (ocular infection, herpetic or neurotrophic keratitis, StevenJohnson Syndrome, etc) 2. Have had penetrating intraocular surgery within 12 months prior to Visit 1 3. Be unwilling to comply with the study requirements</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>DED</keyword>
	<keyword>Disease</keyword>
</DOC>